



Delpazolid

Catalog No: tcsc0018175

Available Sizes
Size: 5mg
Size: 10mg
Size: 25mg
Size: 50mg
Size: 100mg
Specifications
CAS No: 1219707-39-7
Formula: C ₁₄ H ₁₇ FN ₄ O ₃
Pathway: Anti-infection
Target: Bacterial
Purity / Grade: >98%
Solubility: DMSO : 30 mg/mL (97.30 mM; Need ultrasonic and warming)
Alternative Names: LCB01-0371





Observed Molecular Weight:

308.31

Product Description

Delpazolid is a novel oxazolidinone antibiotic agent which can inhibit the growth of **MSSA** and **MRSA** with a MIC_{90} of 2 μ g/mL for both of them.

IC50 & Target: MIC90: 2 μg/mL (MSSA), 2 μg/mL (MRSA)^[1]

In Vitro: Delpazolid (LCB01-0371), at concentrations of 1×MIC and 2×MIC, has bacteriostatic activity against MSSA and MRSA after 24 h. At concentrations of 4×MIC and 8×MIC, Delpazolid shows bacteriostatic activity, but there is no regrowth at concentrations of 4×MIC and 8×MIC after 24 h of incubation^[1]. The survival of *M. abscessus* is greatly decreased in the presence of Delpazolid (LCB-0371) (MIC₅₀=1.2 μ g/mL). Delpazolid dramatically decreases the number of intracellular mycobacteria present at 2 days after infection at concentrations of 0.1, 1, and 10 μ g/mL^[2].

In Vivo: When administered orally, Delpazolid (LCB01-0371) shows potent protective effects against systemic infections caused by Gram-positive and Gram-negative bacteria. Against infection caused by S. aureus Giorgio (MSSA), the ED_{50} of Delpazolid is 4.53 mg/kg of body weight. Against S. aureus p125 (MRSA), the ED_{50} of Delpazolid is 2.96 mg/kg^[1]. When Delpazolid (LCB-0371) is administered at 100 mg/kg daily (by gavage), the colony-forming unit (CFU) counts tend to be decreased in the lungs of mice at 7 days after infection^[2].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!